The development of medical biosensors and nanobiosensors

Robert Steven Marks

doi:10.1016/j.copbio.2011.05.009

Abstract

We describe here the development of various technologiesdeveloped in our laboratory over the years that may be used in theclinical environment. These are based on the fields of chemistry,molecular biology, physics, data mining and chemical engineering.Most have been validated using real-life samples from Africa, Israel,USA, and South America and are discussed as follows:1. Chemiluminescence-basedfiber-opticimmunosensorstopatients infected with viral pathogens (Ebola, Dengue, Hep-aptitis C, West Nile virus, Rift Valley fever) – the BioPenconcept.2. Detection of negative stranded RNA viruses (CCHF, influenza)using reverse genetics cell sensors.3. Biochip immunosensors based on electrogenerated filmsdeposited on ITO chip surfaces.4. Label-less nanometer scale ‘nanoantenna’ immunosensors usingRaman and IR spectroscopies to Epstein Barr EBNA1 or GIPC1antigens.5. Magnetic liquid fiber guide immunosensor for GIPC1 cancer anti-gen.6. Diagnostic phagocytic chemiluminescent imprints to identify

Original language	English
Pages	S15-S15
DOIs	https://doi.org/10.1016/j.copbio.2011.05.009
State	Published - Sep 2011
Event	European Biotechnology Congress 2011 - Duration: 28 Sep 2011 → 1 Oct 2011

Conference

Conference	European Biotechnology Congress 2011
Period	28/09/11 → 1/10/11

Access to Document

10.1016/j.copbio.2011.05.009

Cite this

@conference{a5022a6ff212462e89bf4930d3baf955,

title = "The development of medical biosensors and nanobiosensors",

abstract = "We describe here the development of various technologiesdeveloped in our laboratory over the years that may be used in theclinical environment. These are based on the fields of chemistry,molecular biology, physics, data mining and chemical engineering.Most have been validated using real-life samples from Africa, Israel,USA, and South America and are discussed as follows:1. Chemiluminescence-basedfiber-opticimmunosensorstopatients infected with viral pathogens (Ebola, Dengue, Hep-aptitis C, West Nile virus, Rift Valley fever) – the BioPenconcept.2. Detection of negative stranded RNA viruses (CCHF, influenza)using reverse genetics cell sensors.3. Biochip immunosensors based on electrogenerated filmsdeposited on ITO chip surfaces.4. Label-less nanometer scale {\textquoteleft}nanoantenna{\textquoteright} immunosensors usingRaman and IR spectroscopies to Epstein Barr EBNA1 or GIPC1antigens.5. Magnetic liquid fiber guide immunosensor for GIPC1 cancer anti-gen.6. Diagnostic phagocytic chemiluminescent imprints to identify",

author = "Marks, \{Robert Steven\}",

year = "2011",

month = sep,

doi = "10.1016/j.copbio.2011.05.009",

language = "English",

pages = "S15--S15",

note = "European Biotechnology Congress 2011 ; Conference date: 28-09-2011 Through 01-10-2011",

}

TY - CONF

T1 - The development of medical biosensors and nanobiosensors

AU - Marks, Robert Steven

PY - 2011/9

Y1 - 2011/9

N2 - We describe here the development of various technologiesdeveloped in our laboratory over the years that may be used in theclinical environment. These are based on the fields of chemistry,molecular biology, physics, data mining and chemical engineering.Most have been validated using real-life samples from Africa, Israel,USA, and South America and are discussed as follows:1. Chemiluminescence-basedfiber-opticimmunosensorstopatients infected with viral pathogens (Ebola, Dengue, Hep-aptitis C, West Nile virus, Rift Valley fever) – the BioPenconcept.2. Detection of negative stranded RNA viruses (CCHF, influenza)using reverse genetics cell sensors.3. Biochip immunosensors based on electrogenerated filmsdeposited on ITO chip surfaces.4. Label-less nanometer scale ‘nanoantenna’ immunosensors usingRaman and IR spectroscopies to Epstein Barr EBNA1 or GIPC1antigens.5. Magnetic liquid fiber guide immunosensor for GIPC1 cancer anti-gen.6. Diagnostic phagocytic chemiluminescent imprints to identify

AB - We describe here the development of various technologiesdeveloped in our laboratory over the years that may be used in theclinical environment. These are based on the fields of chemistry,molecular biology, physics, data mining and chemical engineering.Most have been validated using real-life samples from Africa, Israel,USA, and South America and are discussed as follows:1. Chemiluminescence-basedfiber-opticimmunosensorstopatients infected with viral pathogens (Ebola, Dengue, Hep-aptitis C, West Nile virus, Rift Valley fever) – the BioPenconcept.2. Detection of negative stranded RNA viruses (CCHF, influenza)using reverse genetics cell sensors.3. Biochip immunosensors based on electrogenerated filmsdeposited on ITO chip surfaces.4. Label-less nanometer scale ‘nanoantenna’ immunosensors usingRaman and IR spectroscopies to Epstein Barr EBNA1 or GIPC1antigens.5. Magnetic liquid fiber guide immunosensor for GIPC1 cancer anti-gen.6. Diagnostic phagocytic chemiluminescent imprints to identify

U2 - 10.1016/j.copbio.2011.05.009

DO - 10.1016/j.copbio.2011.05.009

M3 - Abstract

SP - S15-S15

T2 - European Biotechnology Congress 2011

Y2 - 28 September 2011 through 1 October 2011

ER -

The development of medical biosensors and nanobiosensors

Abstract

Conference

Access to Document

Fingerprint

Cite this